Lifeboat Foundation

A survey of more than 800 AI systems identified four distinct types of tools.

Back in our childhoods, most of us imagined 2020 as the year filled with flying cars, teleportation devices, and robots that would do everything for us.

Scanning lasers—from barcode scanners at the supermarket to cameras on newer smartphones—are an indispensable part of our daily lives, relying on lasers and detectors for pinpoint precision.

Distance and object recognition using LiDAR—a portmanteau of light and radar—is becoming increasingly common: reflected laser beams record the surrounding environment, providing crucial data for autonomous cars, agricultural machines, and factory robots.

Current technology bounces the laser beams off of moving mirrors, a mechanical method that results in slower scanning speeds and inaccuracies, not to mention the large physical size and complexity of devices housing a laser and mirrors.

The use of artificial intelligence (A.I.) and machine learning (ML), technologies that help people and organizations handle customer personalization and communication, data analytics and processing, and a host of other applications continues to grow.

An IDC report found three-quarters of commercial enterprise applications could lean on A.I. by next year alone, while an Analytics Insight report projects more than 20 million available jobs in artificial intelligence by 2023.

Due to A.I. and ML’s transformational reach, specialists with the right skills could find themselves with job opportunities across a wide range of industries. A global skills gap in the technologies means qualified applicants can expect good salaries and a strong bargaining position.

Donning an augmented reality headset in the cockpit, a veteran F-22 pilot just had a dogfight with a projection of a Chinese J-20 fighter.

Maithra Raghu, a research scientist at Google Brain, is betting that neural networks can become a powerful tool in medicine.

AgelessRx claims that PEARL is the first nationwide telemedicine trial and one of the first large-scale intervention trials on Longevity. The human trial is a stepping stone to the way to bringing rapamycin to the Longevity market. PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a $600,000 trial with the University of California. They will evaluate the safety and effectiveness of rapamycin in 200 healthy adults for Longevity in double-blind, randomized, placebo-controlled trial.

Interested patients will be screened for eligibility using telemedicine. Eligible patients include those aged 50–85 of any sex, any ethnicity, in relatively good health, with only well-managed, clinically stable chronic diseases.

TAME is a separate $75 million trial to clinically evaluate Metformin drugs for Longevity properties. TAME has a composite primary endpoint – of stroke, heart failure, dementia, myocardial infarction, cancer and death. Rather than attempting to cure one endpoint, it will look to delay the onset of any endpoint, extending the years in which subjects remain in good health – their healthspan. A $40 million donation has been combined with a $35 million NIH grant to fund the TAME trial.

Machine-learning system GPT-3 has drawn plaudits from around the world for its remarkable ability to generate text with minimal human input. One scientist even believes it is showing signs of consciousness dailystar.

(next Monday, 23rd November)
Please pre-register at https://www.taufriends.ch/registration

Please pre-register at https://www.taufriends.ch/registration

“We are delighted to bring you access to two giants in the world of AI, 2020 Dan David laureates, Dr. Demis Hassabis, co-founder and CEO of DeepMind, the world’s leading AI research company, and Prof. Amnon Shashua, CEO and co-founder of Mobileye, the largest ever Israeli acquisition whose technology powers more than 55 million cars around the world today. Dr. Hassabis and Prof. Shashua will enlighten us on the potential of AI at an exclusive event in conjunction with the Dan David Prize on Monday, November 23, 2020.”